Background
Histone posttranslational modifications (PTMs) function to regulate chromatin structure and function in part through the recruitment of effector proteins that harbor specialized “reader” domains. Despite efforts to elucidate reader domain–PTM interactions, the influence of neighboring PTMs and the target specificity of many reader domains is still unclear. The aim of this study was to use a high-throughput histone peptide microarray platform to interrogate 83 known and putative histone reader domains from the chromo and Tudor domain families to identify their interactions and characterize the influence of neighboring PTMs on these interactions.

Results: Nearly a quarter of the chromo and Tudor domains screened showed interactions with histone PTMs by peptide microarray, revealing known and several novel methyllysine interactions. Specifically, we found that the CBX/HP1 chromodomains that recognize H3K9me also recognize H3K23me2/3—a poorly understood histone PTM. We also observed that, in addition to their interaction with H3K4me3, Tudor domains of the Spindlin family also recognized H4K20me3—a previously uncharacterized interaction. Several Tudor domains also showed novel interactions with H3K4me as well.

Conclusions: These results provide an important resource for the epigenetics and chromatin community on the interactions of many human chromo and Tudor domains. They also provide the basis for additional studies into the functional significance of the novel interactions that were discovered.

Keywords: Chromatin, Histone methylation, Chromodomain, Tudor domain, Peptide microarray
often each state is associated with distinct genomic locations and unique functional outcomes [14–16]. The major sites of K-methylation on histone H3 are K4, K9, K27, K36, and K79, while K20 is the predominant K-methylation site on histone H4 [14, 15, 17, 18]. Interestingly, histone K-methylation is associated with both transcriptionally permissive and transcriptionally repressive states of chromatin, dependent on the site and degree of methylation. For instance, monomethylation of histone H4 at Lys 20 (H4K20me1) is associated with actively transcribed regions, while trimethylation of H3K9 (H3K9me3) is associated with transcriptionally silent chromatin [19–23]. This suggests that methyllysine readers are specific both for the degree of methylation and for the sequence context surrounding the methylated residue. However, some sites of K-methylation, such as H3K9 and H3K27, share a common ARKS sequence context, suggesting that some reader domains may recognize multiple sites and may require additional factors for specificity. Indeed, many chromatin modifiers and transcriptional machinery contain multiple reader domains that simultaneously engage multiple histone PTMs in a form of “cross-talk” [24]. Furthermore, the residues flanking methyllysine hotspots are often subject to PTMs that may permit or impede binding of methyllysine readers. For example, phosphorylation of serine 10 of H3 (H3S10p) inhibits binding of H3K9me3-specific reader domains, and cis-histone tail H3K9me3/S10p has been observed in cells [25, 26]. Similarly, phosphorylation of H3T3, and to a lesser degree H3T6, impedes binding of H3K4me3-specific reader domains, while symmetrical or asymmetrical dimethylation of H3R2 (H3R2me2s/a) has little effect on certain domain interactions [27], but can block or promote others [28–30]. Known methyllysine reader domains include the plant homeodomain (PHD) fingers, the bromo-adjacent homology (BAH) domains, and the “Royal family” domains [17, 31, 32]. The Royal family of methyllysine readers is conserved throughout eukaryotic evolution and includes the chromo-, Tudor-, PWWP-, and malignant brain tumor (MBT)-structural domains [33]. Members of this family are known to interact with multiple different sites of K-methylation on histones and other proteins. Structural and mechanistic studies of the heterochromatin protein 1 (HP1) chromodomain provided some of the first insights into the molecular mechanism of methyllysine recognition. A co-crystal structure of the HP1 chromodomain bound to an H3K9me3 peptide revealed that a hydrophobic region composed of three conserved aromatic residues stabilizes the interaction with the methyllysine side chain via cation–π and hydrophobic interactions [34]. Additional structure–function studies showed that this “aromatic cage” is a general feature of many methyllysine readers even outside the Royal family [35]. However, the site- and methyl-state specificity for many members of the Royal family is unclear. Moreover, several of the known members of this family are uncharacterized for their interactions with histone PTMs.

While multiple histone K-methylation sites are known, advances in mass spectrometry have increased the number of known sites [36]. However, it is unclear whether the current repertoire of known methyllysine readers, including members of the Royal family, also interacts with these newly identified sites or whether there are distinct readers for each site. In this investigation, we set out to use a high-throughput proteomics approach utilizing customized histone peptide microarrays to survey a large number of human chromo and Tudor domains for their binding to various histone PTMs. We identified several new histone PTM–reader domain interactions for previously characterized readers and identified a subset of H3K9-methyl readers that are also capable of reading H3K23 methylation—a newly identified yet poorly understood histone PTM. The results of our survey will facilitate future studies characterizing the structure–function relationships and biological consequences of these interactions.

Results
We selected 31 chromodomains and 39 Tudor or Tudor-like domains to screen using our histone peptide microarray platform. Several additional protein reader domains were also screened, for a total of 83 proteins screened by peptide microarray (Additional file 1: Table S1). Our peptide microarray platform consists of nearly 300 biotinylated histone peptides harboring unique PTMs at one or more residues immobilized to a streptavidin-coated glass surface (Additional file 2: Table S2) [37, 38]. The arrays were probed in duplicate with purified GST-tagged protein domains, and binding to specific PTMs was detected using fluorescently labeled antibodies (see Methods). Twenty-two of the 83 selected domains showed positive hits with one or more histone peptides on the arrays. As shown in Table 1, many of the known binding targets for these protein domains were detected, as well as several novel interactions. Based on these observations, we focused on further characterizing (1) the novel interaction between Spindlin1 (SPIN1) triple Tudor domain and H4K20me3 and (2) the interaction between several chromodomains and H3K23me2/3.

SPIN1 is a transcriptional coactivator that contains a triple Tudor domain known to interact with H3K4me3—a mark associated with actively transcribed genes [39–41]. As expected, the SPIN1 triple Tudor and several other known H3K4me-binding domains, including the PHD domain of Taf3 and the tandem Tudor domains of JMJD2A and SGF29, strongly interacted with H3K4me2/3 (Fig. 1a; Additional file 3: Figure S1, and Additional file 4: Figure S2). Interestingly, phosphorylation of H3T3 inhibited binding of
SGF29 tandem Tudor and Taf3 PHD, but did not interfere with SPIN1 triple Tudor and JMJD2A tandem Tudor interaction with H3K4me3. In contrast, all of the H3K4me3 reader domains, including CHD1 chromodomain, accommodated H3K4me3 with neighboring H3R2me2a. Furthermore, the chromodomains of CHD7 and CHD9 showed robust interaction with both the unmodified H3 and H4N-terminal tails, while the chromodomain of CHD1 showed interaction with the H4 tail but not with the unmodified H3 tail (Fig. 1a; Additional file 5: Figure S3, Additional file 6: Figure S4, and Additional file 7: Figure S5). In addition, the tandem Tudor of 53BP1 preferentially bound H4K20me1/2 as previously described (Fig. 1a) [42].

Surprisingly, the SPIN1 triple Tudor domain also bound H4K20me3-containing peptides (Fig. 1b, c). This novel interaction was highly reproducible on the peptide microarrays and was confirmed by in-solution peptide pull-down assays (Additional file 3: Figure S1A and S1B). We further validated the specificity of the interaction using peptide pull-down experiments with full-length SPIN1 protein and tested the possibility that other Spen-dlin family members (SPIN2B, SPIN3, and SPIN4) interacted with H4K20me3. Indeed, full-length SPIN1 protein preferentially bound H4K20me3 and showed less interaction with mono- or dimethylated H4K20 (Fig. 1d). Like SPIN1, full-length SPIN2B, SPIN3, and SPIN4 also showed preference for trimethylated H3K4 and H4K20 (Fig. 1d). In order to test whether SPIN1 family members interact with H4K20me3 peptides in the context of the cellular milieu, we transfected 293T cells with constructs containing individual SPIN1 family proteins fused with green fluorescent protein (GFP) and performed peptide pull-down experiments with whole cell lysates. The results from these assays mimic the results obtained using purified proteins, further suggesting that SPIN1 family proteins preferentially interact with H3K4me3 and H4K20me3 in cells (Fig. 1e; Additional file 3: Figure S1C). Notably, while we were unable to purify SPIN2A to high enough quality for use in in vitro pull-down assays using purified proteins, we were able to assess SPIN2A binding to H3K4me3/H4K20me3 peptides using lysates from transfected cells. These results show that, like other SPIN1 family members, SPIN2A is capable of interacting with both H3K4me3 and H4K20me3 (Fig. 1e).

Previous crystallographic analysis of the interaction between SPIN1 triple Tudor and H3K4me3 revealed

---

Table 1 Summary of reader domain interactions identified via histone peptide microarrays

| Protein   | Domain      | Top array hits                   | Known interactions | References |
|-----------|-------------|----------------------------------|--------------------|------------|
| HP1β/CBX1 | Chromo      | H3K9me1/2, H3K23me1/2/3          | H3K9me1/2, H3K23me1/2/3 | [21, 22, 46, 52] |
| HP1γ/CBX3 | Chromo      | H3K9me1/2, H3K23me3              | H3K9me1/2          | [21, 22, 52, 74] |
| HP1α/CBX5 | Chromo      | H3K9me1/2, H3K23me3              | H3K9me1/2          | [21, 48, 52] |
| CDYL1b    | Chromo      | H3K9me1/2, H3K27me2/3            | H3K9me1/2, H3K27me1/2/3 | [75] |
| CDYL2     | Chromo      | H3K9me2/3, H3K27me3              | H3K9me1/2, H3K27me1/2/3 | [76] |
| CHD1      | Chromo (2)  | H3K4me2/3                        | H3K4me3            | [54, 55] |
| CHD7      | Chromo (2)  | H3K4me0                          | H3K4me1/2          | [56] |
| CHD9      | Chromo (2)  | H3K4me0                          | H3K4me1/2          | [56] |
| MPP8      | Chromo      | H3K9me1/2, H3K23me2/3            | H3K9me1/2, H3K23me1/2/3 | [46, 77, 78] |
| S3BP1     | Tudor (2)   | H3K4me2, H3K18me2, H3K36me2, H4K20me1/2 | H3K4me2, H4K20me1/2 | [42, 52] |
| JMJD2A    | Tudor (2)   | H3K4me2/3, H3K18me3, H3K9me3, H4K20me2/3 | H3K4me3, H4K20me2/3 | [51, 52] |
| PHF20     | Tudor (2)   | H3K9me2/3, H4K8me1               | H3K9me2, H3K27me2, H3K36me2 | [35] |
| UHRF1     | Tudor-like  | H3K9me2/3                        | H3K9me2/3          | [79, 80] |
| PHF1      | Tudor       | H3K36me3                         | H3K36me2/3         | [81–84] |
| SGF29     | Double Tudor| H3K4me3                          | H3K4me1/2          | [85] |
| SPIN1     | Triple Tudor| H3K4me2/3, H3K18me3, H4K20me3    | H3K4me2/3          | [40] |
| TDRD2     | Tudor (extended) | H3K4me3                  | H3K4me1/2          | [86] |
| TDRD3     | Tudor       | H3R2me2a, H3R8me2a               | pan-Rme2a          | [53] |
| GLP       | ANK         | H3K9me1/2                        | H3K9me1/2          | [87, 88] |
| ING2      | PHD         | H3K4me2/3                        | H3K4me2/3          | [89] |
| TAF3      | PHD         | H3K4me2/3                        | H3K4me2/3          | [90] |
| L3MBTL1   | MBT (3)     | H3K4me2, H3K9me2, H4K8me1        | H3K4me1/2, H3K9me1/2, H3K27me1/2, H4K20me1/2 | [90–92] |

Italics, validated by peptide pull-down assays

* Novel interactions
Fig. 1 SPIN1 triple Tudor domain interacts with H4K20me3 as well as H3K4me3. 

a Heat map showing the relative binding detected for each of the indicated domains on the peptide microarray platform. Data represent the average of two independent arrays relative to the most intense binding signal within the indicated set of peptides. 

b Scatter plot of the relative binding of SPIN1 triple Tudor domain from two independent peptide arrays. H3K4me3-containing peptides are shown in red and H4K20me3-containing peptides are shown in blue. All other peptides are shown in black. 

c Representative picture of a section of the peptide microarray for SPIN1 triple Tudor domain. The left panel shows both the green (peptide) and red (protein binding) fluorescent channels, while the right panel depicts only the red fluorescence channel for clarity. Positive antibody controls are outlined in white and the positive interaction with the H4K20me3 peptide is outlined in yellow. Full array images are shown in Additional file 3: Figure S1. 

d Western blot results of peptide pull-down experiments with purified full-length Spindlin family members. The input is shown in Lane 1 and the corresponding bound fraction is shown in Lanes 2-8. 

e Western blot results of peptide pull-down experiments with whole cell lysates derived from transiently transfected HEK 293T cells (GFP-SPIN1, 2A, 2B, 3 and 4). 

f Western blot results of peptide pull-down experiments with purified SPIN1 wild type (SPIN1WT) or aromatic cage mutant in the second Tudor domain (SPIN1Y170A) demonstrating a loss of H3K4me3 and H4K20me3 in the mutant.
an aromatic cage in the second Tudor domain of the SPIN1 triple Tudor that coordinates the trimethylated lysine residue [41]. In order to determine whether the interaction with H4K20me3 occurs through the same aromatic cage, we generated a tyrosine 170 to alanine (Y170A) mutation in the aromatic cage of SPIN1 and tested the interaction with H4K20me3 using peptide pull-down analyses. As shown in Fig. 1f, the Y170A variant showed minimal interaction with both H3K4me3 and H4K20me3. The SPIN1 Y170A mutation was previously shown to disrupt H3K4me3 binding [43]; thus, our results suggest that H4K20me3 is coordinated in the same aromatic pocket. Additional structural and functional studies show that H3R8me2a enhances the binding of SPIN1 to H3K4me3-containing peptides [43]. The methylated Arg8 side chain is coordinated in a hydrophobic pocket in the first Tudor domain of SPIN1, while the H3K4me3 residue is coordinated in the second Tudor domain [43]. In order to confirm that the Y170A mutant specifically disrupts the second Tudor domain, we tested the interaction of SPIN1 with a peptide containing the double H3K4me3/H3R8me2a modification. Both wild-type SPIN1 and the Y170A variant showed enhanced interaction with the H3K4me3/H3R8me2a peptide compared to the H3K4me3 peptide, suggesting specific disruption of the second Tudor domain in the Y170A variant (Fig. 1f). Together, these results indicate that the second Tudor domain of SPIN1 can bind both H3K4me3 and H4K20me3 in a mutually exclusive manner.

The second novel interaction we detected occurred between several chromodomains and H3K23me peptides. As shown in Fig. 2a, the chromodomains of CBX1, CBX3, CBX5, CDYL2, and MPP8 showed strong interaction with H3K9me3, even in the context of neighboring arginine 8 asymmetrical or symmetrical dimethylation. In all cases, H3S10phos inhibited the interaction with H3K9me3 and there was a clear preference for H3K9me3 over H3K27me3. In addition to the well-characterized interactions with H3K9me3, we also observed binding to H3K23me-containing peptides. To validate these interactions, we performed peptide pull-down experiments with H3K9, H3K23, and K3K27 peptides with varied degrees of methylation. As shown in Fig. 2b, we observed that CBX1, CBX3, CBX5, and MPP8 chromodomains interacted with H3K9me1/2/3 peptides and H3K23me2/3 peptides, but showed minimal interactions...
with H3K27me1/2/3 peptides. CDYL1B and CDYL2 showed preference for H3K9me2/3 peptides and very weak interactions with H3K23me peptides and H3K27me peptides. These results suggest that members of the CBX family of H3K9me3 reader domains, which have high selectivity for H3K9 over a very similar sequence motif at H3K27 (i.e., ARKS), are robust readers of H3K23 methylation, thus implicating H3K23 methylation, along with H3K9me, in the silencing functions of these domains.

Discussion

The aim of this study was to create a valuable resource of chromo and Tudor reader domains for their interactions and cross-talk between histone PTMs. This work was facilitated by the use of a high-throughput approach employing peptide microarrays containing nearly 300 biotinylated histone peptides harboring up to five PTMs on each peptide (Additional file 2: Table S2). While several other histone peptide microarray platforms have been described [44–47], there are several notable features of our peptide array platform that aided the current study. These include highly purified peptides of lengths greater than 20 amino acids, along with each peptide being spotted multiple times by multiple pins to provide a robust number of data points that gave us high confidence in the interactions (and changes in these interactions by neighboring PTMs) that we observed.

Our survey of histone reader domains is one of the largest screens for histone PTM–reader domain interactions to date. We expressed and purified 83 protein domains, including 31 chromodomains and 39 Tudor or Tudor-like domains. We screened each domain in duplicate, and 22 domains exhibited consistent, reproducible binding to histone peptides on our arrays. The majority of the protein domains we tested, however, did not exhibit binding to histone peptides (see full list of domains screened in Additional file 1: Table S1). There are several possible explanations for this. First, our previous observations suggest that binding affinities weaker than approximately 30 µM are typically beyond the limit of detection for this platform [37]. It is notable that many reader domains exhibit weak interactions with histone peptides, which may account for a substantial number of negatives in our screen. For example, the chromodomain of CBX2 has been shown to bind H3K9me3 and H3K27me2 peptides with a binding affinity of ~40 µM via fluorescence polarization [48], which would explain why this chromodomain failed to show PTM interactions as compared to the other CBX domains. Second, we screened several protein domains with unknown histone PTM binding targets. For example, the Tudor domains of TDRD1 and TDRD2 are known to interact with methylated Piwi proteins [49, 50], but there are no known methyl-histone binding targets known to date. Similarly, TDRD4, TDRD9, and several other TDRD family members have no known methyl-histone binding targets, and it is possible that these Tudor domains do not interact with histones. Third, the recombinant protein domains we expressed and purified may require additional sequences from their respective proteins that are needed for histone PTM binding and are not present in the domains we designed. Indeed, the single Tudor domain of PHF20 was negative on our arrays, but the tandem Tudor domain interacted with H3K9me2, as previously shown [35]. In addition, the domains we purified may require interaction with other proteins in order to bind histones. Finally, it is possible that the conditions we used in this high-throughput approach were not amenable to binding for some proteins.

Of the 31 Tudor or Tudor-like domains we screened, several known interactions were detected on our arrays (Table 1). Both 53BP1 and JMJD2A tandem Tudor domains showed binding to H3K4me and H4K20me peptides as previously shown [42, 51, 52]. Some novel interactions were also detected on the peptide arrays, such as binding to H3K18me, but further experiments need to be performed to validate these findings. TDRD3 Tudor domain specifically recognized asymmetrically dimethylated peptides, as previously shown [53], but our results suggest that this Tudor domain has broad affinity for Rme2a-containing peptide (Additional file 8: Figure S6 and Table 1). Of the 39 chromodomains we surveyed, nearly 20% interacted with modified histone peptides. Many of these interactions are well-characterized, such as binding to H3K9me peptides by the CBX family of proteins [21, 22, 52]. We also observed interaction between CHD1 chromodomain and H3K4me3 as previously described [54, 55]. Intriguingly, the chromodomains of CHD1, CHD7, and CHD9 all showed interactions with unmodified histone H4 peptide, and CHD7 and CHD9 also interacted with unmodified histone H3 peptide (Additional file 5: Figure S3, Additional file 6: Figure S4, Additional file 5: Figure S5, and Table 1). Although CHD9 chromodomains have not been shown to bind methylated histones, H3K4me1/2/3 peptides were shown to competitively disrupt histone interactions with purified histones, which is in agreement with the idea that the H3N terminus can bind the chromodomain of CHD9 [56]. It should be noted that unmodified histone H3 peptides were not tested in these experiments, but based on our findings, we speculate the K4 unmodified peptide would have also competed CHD9 chromodomain interaction given our results show general H3 binding without preference to the H3K4 methyl state.

Due to the large scope of this microarray screen, we focused on validating only a subset of interactions by peptide pull-down experiments. The two most significant
and novel interactions we uncovered were with H3K23me and H4K20me peptides. First, we observed that several chromodomains interacted with H3K23me, in addition to the known H3K9me targets. MFP8 and CBX1 chromodomains have been shown to interact with H3K23me peptides at low micromolar binding affinities [46]. We confirmed these results in our screen and observed that additional chromodomains, CBX3 and CBX5, also interact with H3K23me2/3. In our study, we observed preferential binding to di- and trimethylated states of H3K23. All three methylation states of H3K23 have been detected in cells [46], and a recent report suggests that H3K23me3 colocalizes with H3K27me3 and plays a role in protecting heterochromatin from double-strand DNA breaks during meiosis [57]. It is possible that the dual modification may provide an even better binding substrate for these chromodomains, which will be interesting to explore in future biological studies. In contrast, the CDY family members that exhibited binding on our arrays (CDYL1B and CDYL2) showed preference for H3K9me3 and did not interact with H3K23me peptides. Notably, a recent report suggested that H3K23 methylation regulates levels of H3K36 methylation by recruiting the H3K36 demethylase, KDM4B, via its double Tudor domain [58]. However, none of the Tudor domains surveyed here showed interaction with H3K23 methylation.

We also focused on the novel interaction between the SPIN1 Tandem Tudor domain and H4K20me2/3, which we validated by peptide pull-down experiments and demonstrated with other Spindlin family members (Fig. 1d). In the context of full-length protein, SPIN1 shows remarkable preference for trimethylation at H3K4 and H4K20. SPIN2B and SPIN3 show similar selectivity, while SPIN4 seems to accommodate both di- and trimethylated H4K20. SPIN2B and SPIN3 show similar selectivity, while SPIN4 seems to accommodate both di- and trimethylated H4K20me3. SPIN1 is composed of three homologous Tudor domains denoted I, II, and III [39]. The second Tudor domain (II) is composed of the aromatic residues Phe 141, Trp 151, Tyr 170, and Tyr 177, which together form the aromatic cage that coordinates the methyl lysine [41]. Our observation that the Tyr170All variant loses interaction with both H3K4me3 and H4K20me3 suggests that domain II is responsible for recognizing both modifications. This further suggests that SPIN1 interacts with H3K4me3 and H4K20me3 at different times and/or different genomic locations, possibly under different cellular conditions.

Lysine 20 is the predominant methylation site on H4, and this modification is important for development in higher eukaryotes (reviewed in [59]). H4K20 methylation is associated with regulating transcription, the DNA damage response, and cell cycle progression [59]. Multiple H4K20 methyl readers have been described, and many of them contain a Tudor or Tandem Tudor domain like SPIN1 [59]. These readers of H4K20me are thought to mediate the cellular roles ascribed to H4K20 methylation. For instance, the Tandem Tudor domain of 53BP1 is required for localization of 53BP1 to sites of DNA damage where it acts as a mediator of DNA damage signaling and repair [42, 60, 61]. Interestingly, different levels of H4K20 methylation are associated with different effects on transcription. For instance, H4K20me1 is associated with active transcriptional states of chromatin, while H4K20me3 is associated with transcriptionally silent chromatin regions [19, 62, 63]. Our data suggest that SPIN1 and other Spindlin family members are capable of recognizing both a transcriptional activation modification (i.e., H3K4me3) and a transcriptional silencing modification (i.e., H4K20me3). This result is, to the best of our knowledge, the first example of a reader domain that can read both activating and deactivating histone PTMs.

As H4K20 methylation is important in several cellular processes, aberrant H4K20 methylation is observed in several cancers and mutations in H4K20 methyl reader domains have been described in human developmental disorders [64–66]. Furthermore, SPIN1 is overexpressed in several varieties of malignant tumors and upregulation of SPIN1 is known to increase cellular proliferation and cause chromosomal instability and abnormal mitosis [67–71]. The interaction of SPIN1 with H4K20me2/3 may play a part in mediating some of the roles associated with H4K20 methylation, but additional in vivo studies are needed to determine the biological importance of this interaction. Chemical probes that inhibit the interaction of SPIN1 with H3K4me3 peptides in vitro have been described [72, 73]. Our work suggests that these probes could also be useful tools for characterizing the SPIN1-H4K20me interaction in vivo.

Conclusions

This high-throughput screen aimed to determine the histone PTM binding targets of known and putative chromo and Tudor reader domains to create a valuable resource for future studies of these domains. Our survey encompassed the majority of human chromo and Tudor domains, and uncovered known and unknown histone PTM interactions. Of the many hits we observed, we focused on two novel interactions: (1) chromodomain recognition of H3K23me and (2) recognition of H4K20me3 by the Spindlin family of proteins. Future work will be needed to uncover the importance of these interactions in vivo.

Methods

Protein expression and purification

Codon optimized constructs were synthesized and cloned into pGEX-4T-1 expression vectors (GE
Healthcare) by Biomatik. Proteins were expressed in soluble BL21 (DE3) (Amsbio) grown in Terrific Broth II media (MP Biomedicals). After culturing at 37 °C until an OD_{600} of ~0.6, cells were chilled for 30 min at 4 °C before induction with 1 mM IPTG for 20 h at 16 °C. Cells were harvested by centrifugation and pellets were flash frozen in liquid nitrogen. For purification, thawed cell pellets were resuspended in binding buffer (50 mM Tris pH 7.5, 250 mM NaCl, 4 mM DTT, 10% glycerol) supplemented with a protease inhibitor cocktail (Roche), 0.1 mM phenylmethane sulfonl fluoride (PMSF), 0.5 mg/ml chicken egg lysozyme (Sigma), and 0.2% (v/v) Triton X-100. After incubation on ice for 45 min, cells were lysed by sonication and clarified by centrifugation. Lysates were incubated with glutathione agarose (Pierce) and then washed with 10 bed volumes of binding buffer. Bound protein was eluted with elution buffer (50 mM Tris pH 8.0, 250 mM NaCl, 4 mM DTT, 10% glycerol, 10 mM reduced glutathione) and then dialyzed against 3 l of binding buffer at 4 °C. Samples were concentrated by centrifugation and protein concentration and purity were determined by Bradford Assay (BioRad) and SDS-PAGE, respectively.

**Peptide microarrays**

The peptide microarrays were generated and assayed as described previously [37, 38], except that the arrays contained four triplicate spots of each peptide. Briefly, GST-tagged proteins were diluted to 0.5–2 μM in phosphate-buffered saline (PBS) supplemented with 0.1% (v/v) Tween-20 (PBST) and 5% (w/v) bovine serum albumin (BSA, EMD Millipore Omnipure Fraction V) and incubated with peptide microarrays overnight at 4 °C. Arrays were washed three times with PBS and then probed with an anti-GST antibody (EpiCypher Inc.; Cat. No. 13-0022) diluted to 1:1000 in PBST + 5% BSA. Arrays were washed again 3× with PBS and then probed with an Alexa Fluor 647-conjugated anti-rabbit antibody at 1:10,000 (ThermoFisher). Arrays were imaged using a Typhoon Scanner and protein binding was determined as previously described [37, 38]. The average signal intensity for each peptide was normalized to the most intense binding within an array, and normalized binding was averaged for at least two independent replicates for each protein. Heat maps of relative binding were generated using JavaTree View (version 1.16r4) after normalizing the relative binding within the subset of peptides selected for the heat map.

**In-solution peptide pull-down assays**

For pull-down experiments using purified proteins, a total of 50 pmol of GST-tagged protein was incubated with 500 pmols of biotinylated histone peptide for 1 h at 4 °C in peptide binding buffer (50 mM Tris pH 8.0, 300 mM NaCl, 0.1% NP-40). Following incubation, the protein–peptide mixture was incubated with streptavidin-coated magnetic beads (Pierce) and pre-equilibrated with peptide binding buffer, for 1 additional hour at 4 °C. The beads were washed three times with peptide binding buffer, and bound complexes were eluted with 1x SDS loading buffer, then resolved via SDS-PAGE and transferred to a PVDF membrane. The membrane was probed with an anti-GST antibody (EpiCypher Inc.; Cat. No. 13-0022) diluted 1:4000 in PBST supplemented with 5% (w/v) BSA (Sigma).

For pull-down experiments using cell lysates, HEK 293T cells were transiently transfected with GFP-SPIN1, 2A, 2B, 3, and 4 using polyethylenimine according to manufacturer’s instructions. Cells were lysed in ice-cold mild lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2) containing protease inhibitor cocktail (Roche). Thirty microliter of streptavidin agarose beads (Millipore) was pre-washed with binding buffer and incubated with 10 μg of biotinylated histone peptides for 2 h with rocking at 4 °C. The beads were then washed three times with 500 μl binding buffer to remove unbound peptide. The peptide–streptavidin agarose mix was then incubated overnight with the whole cell lysates and rocked at 4 °C. After three washes with 500 μl binding buffer, 30 μl of 2× SDS loading buffer was added to the beads and boiled. The samples were subjected to SDS-PAGE and Western blotting analysis using polyclonal GFP antibody (Santa Cruz Biotech, 1:3000).

**Additional files**

- **Additional file 1: Table S1.** Protein domains screened by histone peptide microarray.
- **Additional file 2: Table S2.** Histone peptide library used for peptide microarrays.
- **Additional file 3: Figure S1.** SPIN1 Tudor domain interaction with H3K4me3 and H4K20me3. A) Representative array images of SPIN1 Tudor domain showing peptide binding indicated in red (right panel). The peptide tracer is shown in green (left panel). Positive antibody controls are outlined in white. B) Western blot results of peptide pull-down experiments with SPIN1 tandem Tudor domain. The input is shown in Lane 1 and the corresponding bound fraction is shown in Lanes 2–8. C) Western blot results of peptide pull-down experiments with whole cell lysates derived from transiently transfected HEK 293T cells (GFP-SPIN1, 2A, 2B, 3 and 4).
- **Additional file 4: Figure S2.** Peptide microarray data for SGF29 and Taf3. Representative array images of A) SGF29 double Tudor domain and Taf3 PHD domain showing peptide binding indicated in red (right panel). The peptide tracer is shown in green (left panel). Positive antibody controls are outlined in white. B) Scatter plot of the relative binding of CHD1 chromodomain from...
two independent peptide arrays. All modified and unmodified H4 (1–23) peptides are shown in blue, and H3K4me2/3-containing peptides are shown in red. All other peptides are shown in black. A) Relative binding to the indicated histone peptides from two representative arrays. Data were normalized to the most intense binding and the average and standard deviation of triplicate spots is shown.

Additional file 6: Figure S4. CHD7 chromodomain histone peptide microarray. A) Representative array images of CHD7 chromodomain showing peptide binding indicated in red (right panel). The peptide tracer is shown in green (left panel). Positive antibody controls are outlined in white. B) Scatter plot of the relative binding of CHD7 chromodomain from two independent peptide arrays. All modified and unmodified H4 (1–23) peptides are shown in red. All other peptides are shown in black. C) Relative binding to the indicated histone peptides from one representative array. Data were normalized to the most intense binding and the average and standard deviation of triplicate spots is shown.

Additional file 7: Figure S5. CHD9 chromodomain histone peptide microarray. A) Representative array images of CHD9 chromodomain showing peptide binding indicated in red (right panel). The peptide tracer is shown in green (left panel). Positive antibody controls are outlined in white. B) Scatter plot of the relative binding of CHD9 chromodomain from two independent peptide arrays. All modified and unmodified H4 (1–23) peptides are shown in red. All other peptides are shown in black. C) Relative binding to the indicated histone peptides from one representative array. Data were normalized to the most intense binding and the average and standard deviation of triplicate spots is shown.

Additional file 8: Figure S6. TDRD3 Tudor domain histone peptide microarray. A) Representative array images of TDRD3 Tudor domain showing peptide binding indicated in red (right panel). The peptide tracer is shown in green (left panel).

Abbreviations
BAH: bromo-adjacent homology; GST: glutathione S-transferase; MBT: malignant brain tumor; PBS: phosphate-buffered saline; PHD: plant homeodomain; PTM: posttranslational modification.

Authors’ contributions
EKS, SAS, MTB, and BDS designed the study. EKS, SAS, JBB, and SBR performed the experiments. NB and CS generated the recombinant effector domains. EKS and SAS analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Biological and Environmental Sciences, Longwood University, Farmville, VA 23909, USA. 2 Department of Biochemistry and Biophysics, The University of North Carolina, Chapel Hill, NC 27599, USA. 3 Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA. 4 Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX 78957, USA. 5 Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI 49503, USA. 6 Present Address: Roy & Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA.

Acknowledgements
We would like to acknowledge Ian Tsun and Lucas Aponte for help with protein purification and peptide pull-down experiments.

Competing interests
BDS and MTB acknowledge being co-founders of EpiCypher, Inc.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding authors on request.

Funding
EKS was supported in part through Longwood University and by the NIGMS IRACDA Grant K12-GM000678. SAS was funded through a UNC Lineberger Cancer Center Postdoctoral Fellowship. BDS is supported by NIH Grant GM100588. MTB is supported by NIH Grant DK062248. SBR is supported by NIH Grant CA181343.

Received: 17 January 2017 Accepted: 1 March 2017
Published online: 14 March 2017

References
1. Luger K, Hansen JC. Nucleosome and chromatin fiber dynamics. Curr Opin Struct Biol. 2015;35:105–9.
2. Li G, Reinberg D. Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev. 2011;21:175–86.
3. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407–12.
4. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21:381–95.
5. Gardner KE, Allis CD, Strahl BD. Operating on chromatin, a colorful language where context matters. J Mol Biol. 2011;409:36–46.
6. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41–5.
7. Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biophys Acta (BBA) Gene Regul Mech. 2014;1839:627–43.
8. Kouzarides T. Chromatin modifications and their function. Cell. 2011;147:693–705.
9. Muselman CA, Lalonde ME, Cote J, Kutateladze TG. Perceiving the epigenetic landscape through histone readers. Nat Struct Mol Biol. 2012;19:1218–27.
10. Taverna SD, Li H, Rutherford AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14:1025–40.
11. Daniel JA, Pray-Grant MG, Grant PA. Effector proteins for methylated histones: an expanding family. Cell Cycle. 2005;4:919–26.
12. Bottomley MJ. Structures of protein domains that create or recognize histone modifications. EMBO Rep. 2004;5:464–9.
13. Herold JM, Ingerman LA, Gao C, Frye SV. Drug discovery toward antagonists of methyl-lysine binding proteins. Curr Chem Genomics. 2011;5:51–61.
14. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2006;7:838–49.
15. Lachner M, O’ Sullivan RJ, Jenewein T. An epigenetic road map for histone lysine methylation. J Cell Sci. 2003;116:2117–24.
16. Black JC, Van Rechem C, Whetstone JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48:491–507.
17. Patel DJ. A structural perspective on readout of epigenetic histone and DNA methylation marks. Cold Spring Harb Perspect Biol. 2016;8:a018754.
18. Moore KE, Gozani O. An unexpected journey: lysine methylation across the proteome. Biochim Biophys Acta (BBA) Gene Regul Mech. 1839;2014:1395–403.
19. Banki A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. High-resolution profiling of histone modifications in the human genome. Cell. 2007;129:823–37.
20. Li Z, Nie F, Wang S, Li L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci. 2011;108:3116–23.
21. Bannister AJ, Zegerman P, Partridge JF, Milaka EA, Thomas JC, Allshire RC, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001;410:120–4.
22. Lachner M, O’Carroll D, Rea S, Mechtler K, Jenewein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001;410:116–20.
23. Schotta G, Ebert A, Krauss V, Fischer A, Hoffmann J, Rea S, et al. Central role of Drosophila SU (VAR) 3–9 in histone H3-K9 methylation and heterochromatin gene silencing. EMBO J. 2002;21:1121–31.
24. Suganuma T, Workman J. Crosstalk among histone modifications. Cell. 2008;135:491–507.
25. Sirotkin K, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2006;7:838–49.
26. Bottomley MJ. Structures of protein domains that create or recognize histone modifications. EMBO Rep. 2004;5:464–9.
27. Herold JM, Ingerman LA, Gao C, Frye SV. Drug discovery toward antagonists of methyl-lysine binding proteins. Curr Chem Genomics. 2011;5:51–61.
28. Daniel JA, Pray-Grant MG, Grant PA. Effector proteins for methylated histones: an expanding family. Cell Cycle. 2005;4:919–26.
29. Bottomley MJ. Structures of protein domains that create or recognize histone modifications. EMBO Rep. 2004;5:464–9.
30. Moore KE, Gozani O. An unexpected journey: lysine methylation across the proteome. Biochim Biophys Acta (BBA) Gene Regul Mech. 1839;2014:1395–403.
31. Banki A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. High-resolution profiling of histone modifications in the human genome. Cell. 2007;129:823–37.
32. Li Z, Nie F, Wang S, Li L. Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci. 2011;108:3116–23.
33. Bannister AJ, Zegerman P, Partridge JF, Milaka EA, Thomas JC, Allshire RC, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001;410:120–4.
34. Lachner M, O’Carroll D, Rea S, Mechtler K, Jenewein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001;410:116–20.
35. Schotta G, Ebert A, Krauss V, Fischer A, Hoffmann J, Rea S, et al. Central role of Drosophila SU (VAR) 3–9 in histone H3-K9 methylation and heterochromatin gene silencing. EMBO J. 2002;21:1121–31.
36. Suganuma T, Workman J. Crosstalk among histone modifications. Cell. 2008;135:491–507.
37. Sirotkin K, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2006;7:838–49.
26. Fischle W, Tseng BS, Dorrmann HL, Ueberheide BM, Garcia BA, Shabanowitz J, et al. Regulation of HP1-chromatin binding by histone H3 methyl-lation and phosphorylation. Nature. 2005;438:1116–22.

27. Gatchalian J, Gallardo CM, Shinsky SA, Ospina RR, Liendo AM, Krajewski K, et al. Chromatin condensation and recruitment of PHD finger proteins to histone H3K4me3 are mutually exclusive. Nucleic Acids Res. 2016;44:6102–12.

28. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S, et al. Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem. 2008;283:3006–10.

29. Migliori V, Muller J, Phalke S, Low D, Bezzi M, Mok WC, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nat Struct Mol Biol. 2012;19:136–44.

30. Hyllus D, Stein C, Schnabel K, Schiltz E, Imhof A, Dou Y, et al. PRMT6-medi- ated methylation of R2 in histone H3 antagonizes H4 trimethylation. Genes Dev. 2007;21:3369–80.

31. Yap KL, Zhou M-M. Keeping it in the family: diverse histone recogni-tion by conserved structural folds. Crit Rev Biochem Mol Biol. 2010;45:488–505.

32. Shi X, Kachriskaja I, Walter KL, Kuo J-HA, Lake A, Davazou F, et al. Proteome-wide analysis in Saccharomyces cerevisiae identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylation at either lysine 4 or lysine 36. J Biol Chem. 2007;282:2450–5.

33. Maurer-Stroh S, Dickens NJ, Hughes-Davies L, Kouzarides T, Eisenhaber F, Ponting CP. The Tudor domain “Royal Family”: tudor, plant agenet, chromo, PWWP and MBT domains. Trends Biochem Sci. 2003;28:697–704.

34. Jacobs SA, Khosravanzadeh S. Structure of HP1 chromodomain bound to a lysine 9-methylated histone H3 tail. Science. 2002;295:2080–3.

35. Adams-Cioaba MA, Li Z, Tempel W, Guo Y, Bian C, Li Y, et al. Crystal structures of the Tudor domains of human PHF20 reveal novel structural variations on the Royal Family of proteins. FEBS Lett. 2012;586:859–65.

36. Washburn MP, Zhao Y, Garcia BA. Reshaping the chromatin and epige-netic landscapes with quantitative mass spectrometry. Mol Cell Proteom. 2016;15:753–4.

37. Rothbart SB, Krajewski K, Strahl BD. Peptide microarrays to study histone arginine methylation. J Biol Chem. 2010;285:12109–14.

38. Chen C, Jin J, James DA, Adams-Cioaba MA, Park JG, Guo Y, et al. Mouse Spindlin1 induces metaphase arrest and chromosomal instability. J Cell Physiol. 2008;217:400–8.
71. Yuan H, Zhang P, Qin L, Chen L, Shi S, Lu Y, et al. Overexpression of SPINDLIN1 induces cellular senescence, multinucleation and apoptosis. Gene. 2008;410:67–74.

72. Robaa D, Wagner T, Luise C, Carlini L, McMillan J, Flagg R, et al. Identification and structure-activity relationship studies of small-molecule inhibitors of the methyllysine reader protein Spindlin1. ChemMedChem. 2016;11:2327–38.

73. Wagner T, Greschik H, Burgahn T, Schmidtkunz K, Schott A-K, McMillan J, et al. Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform. Nucleic Acids Res. 2016;44:e88.

74. Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, et al. Recognition and specificity determinants of the human Cbx chromodomains. J Biol Chem. 2011;286:5201–9.

75. Franz H, Mosch K, Soerées S, Urlaub H, Fischle W. Multimerization and H3K9me3 binding are required for CDYL1b heterochromatin association. J Biol Chem. 2009;284:35049–59.

76. Fischle W, Franz H, Jacobs SA, Allis CD, Khorasanizadeh S. Specificity of the chromodomain Y chromosome family of chromodomains for lysine-methylated ARK (S/T) motifs. J Biol Chem. 2008;283:19626–35.

77. Kokura K, Sun L, Bedford MT, Fang J. Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. EMBO J. 2010;29:3673–87.

78. Chang Y, Horton JR, Bedford MT, Zhang X, Cheng X. Structural insights for MPP8 chromodomain interaction with histone H3 lysine 9: potential effect of phosphorylation on methyl-lysine binding. J Mol Biol. 2011;408:807–14.

79. Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M, et al. Recognition of multivalent histone states associated with heterochromatin by CDYL1b. J Biol Chem. 2011;286:24300–11.

80. Rothbart SB, Krajewski K, Nady N, Tempel W, Xue S, Badeaux AI, et al. Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat Struct Mol Biol. 2012;19:1155–60.

81. Musselman CA, Avvakumov N, Watanabe R, Abraham CG, Lalonde M-E, Hong Z, et al. Molecular basis for H3K36me3 recognition by the Tudor domain of PHF1. Nat Struct Mol Biol. 2012;19:1266–72.

82. Ballaré C, Lange M, Lapinate A, Martin GM, Morey L, Pascual G, et al. Phf19 links methylated Lys36 of histone H3 to regulation of Polycomb activity. Nat Struct Mol Biol. 2012;19:1257–65.

83. Cai L, Rothbart SB, Lu R, Xu B, Chen W-I, Tripathy A, et al. An H3K36 methylation-creating Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell. 2013;49:571–82.

84. Qin S, Guo Y, Xu C, Bian C, Fu M, Gong S, et al. Tudor domains of the PRC2 components PHF1 and PHF19 selectively bind to histone H3K36me3. Biochem Biophys Res Commun. 2013;430:547–53.

85. Bian C, Xu C, Ruan J, Lee KK, Burke TL, Tempel W, et al. Sgf29 binds histone H3K4me2/3 and is required for SAGA complex recruitment and histone H3 acetylation. EMBO J. 2011;30:2829–42.

86. Collins RE, Northrop JP, Horton JR, Lee DY, Zhang X, Stallcup MR, et al. The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat Struct Mol Biol. 2008;15:245–50.

87. Pena PV, Davrazou F, Shi X, Walter KL, Verkhusha VV, Geozzi O, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature. 2006;442:100–3.

88. Shi X, Hong T, Walter KL, Ewalt M, Michishita E, Hung T, et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature. 2006;442:96–9.

89. Vermeulen M, Mulder KW, Denissov S, Pijnappel WW, van Schaik FM, Varier RA, et al. Selective anchoring of TFIIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007;131:58–69.

90. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin conformations by linked binding modules. Nat Rev Mol Cell Biol. 2007;8:983–94.

91. Min J, Allali-Hassani A, Nady N, Ouyang H, Liu Y, et al. L3MBTL1 recognition of mono- and dimethylated histones. Nat Struct Mol Biol. 2007;14:1229–30.

92. Trojer P, Li G, Sims RJ, Vaquer A, Kalakonda N, Bocchini P, et al. L3MBTL1, a histone-methylation-dependent chromatin lock. Cell. 2007;129:915–28.